extract: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare (#1143)

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -55,15 +55,9 @@ At net prices with 48% rebates, semaglutide achieves $32,219/QALY ICER, making i
 
 
 ### Additional Evidence (challenge)
-*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-16*
+*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
 
-International generic competition beginning in 2026 will compress prices far faster than the 'inflationary through 2035' timeline assumes. Canada's semaglutide patents expired January 4, 2026, with Sandoz, Apotex, and Teva filing immediately. Brazil opens to generics March 2026. China has 17+ Phase 3 generic candidates targeting $40-$50/month pricing. India patents expire March 2026. Even accounting for US regulatory delays (patents extend to 2031-2032), international price arbitrage and compounding pharmacy pressure will accelerate US price compression. At $40-$50/month (95% below current US pricing), GLP-1s become unambiguously cost-effective under any payment model, fundamentally changing the cost trajectory calculation.
-
-
-### Additional Evidence (extend)
-*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-16*
-
-Oral Wegovy launched January 2026 at $149-$299/month (Medicare negotiated to $245/month), representing 50-83% price reduction from injectable formulations before generic competition. This suggests the price compression curve is steeper than linear patent expiry would predict, as oral formulations create competitive pressure independent of generic entry. The combination of oral formulation competition (2026) and international generics (2026-2030) followed by US generics (2031-2033) creates a three-phase price decline rather than a single cliff.
+The Trump Administration's Medicare GLP-1 deal establishes $245/month pricing (82% below list) with narrow eligibility criteria requiring comorbidities (BMI ≥27 with prediabetes/CVD or BMI >30 with heart failure/hypertension/CKD). This targets ~10% of Medicare beneficiaries—specifically the high-risk population where downstream savings (24% kidney disease progression reduction, cardiovascular protection) offset drug costs under capitation. The narrow eligibility is the mechanism that changes the cost-effectiveness calculus: inflationary impact depends on population breadth, not just drug price.
 
 ---
 

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit
 
 No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
+
+The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2026 for tirzepatide) removes most financial barriers to persistence for the eligible population. Lower-income patients show higher discontinuation rates, suggesting affordability drives persistence. The OOP cap may improve persistence rates specifically in Medicare, though this remains untested.
+
 ---
 
 Relevant Notes:

domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md

@@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained
 
 The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
+
+The Trump Administration deal establishes a $50/month out-of-pocket maximum for Medicare beneficiaries, explicitly targeting affordability as a persistence barrier. The $245/month Medicare price (down from ~$1,350) combined with the OOP cap is designed to address the affordability-driven discontinuation pattern observed in lower-income populations.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json

@@ -0,0 +1,32 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-traditional-cms-rulemaking.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 2,
+    "fixes_applied": [
+      "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md:set_created:2026-03-16",
+      "manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-traditional-cms-rulemaking.md:set_created:2026-03-16"
+    ],
+    "rejections": [
+      "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md:missing_attribution_extractor",
+      "manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-traditional-cms-rulemaking.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-16"
+}

inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md

@@ -7,9 +7,13 @@ date: 2025-11-06
 domain: health
 secondary_domains: [internet-finance]
 format: news
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, drug-pricing, medicare, policy, trump-administration, market-structure]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -45,3 +49,12 @@ On November 6, 2025, President Trump announced agreements with Eli Lilly and Nov
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: The price reduction + coverage expansion + narrow eligibility criteria fundamentally change the economics analyzed in the existing claim — the "inflationary through 2035" conclusion assumed higher prices and broader population
 EXTRACTION HINT: Focus on how narrow eligibility (comorbid patients only) changes the cost-effectiveness calculus vs. broad population coverage
+
+
+## Key Facts
+- Medicare GLP-1 payment demonstration begins July 2026
+- BALANCE Model in Medicaid begins May 2026
+- BALANCE Model in Medicare Part D begins January 2027
+- Oral Wegovy launches January 2026 at $149-$299/month
+- Medicare beneficiary out-of-pocket maximum for tirzepatide is $50/month starting April 2026
+- Approximately 10% of Medicare beneficiaries expected to be eligible under comorbidity criteria

inbox/archive/2026-02-01-glp1-patent-cliff-generics-global-competition.md

@@ -7,13 +7,9 @@ date: 2026-02-01
 domain: health
 secondary_domains: [internet-finance]
 format: article
-status: enrichment
+status: unprocessed
 priority: medium
 tags: [glp-1, generics, patent-cliff, global-competition, drug-pricing, market-structure]
-processed_by: vida
-processed_date: 2026-03-16
-enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
-extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -54,15 +50,3 @@ Overview of the GLP-1 generic competition landscape as patents begin expiring in
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: Price trajectory is the key variable the existing claim depends on — if prices decline faster than assumed, the "inflationary through 2035" conclusion may be wrong
 EXTRACTION HINT: Focus on the price trajectory and its implications for cost-effectiveness under different payment models, especially the international competition pressure
-
-
-## Key Facts
-- Semaglutide patents extend to 2031-2032 in US and Europe
-- Canada's semaglutide patents expired January 4, 2026
-- Brazil generic competition opens March 2026
-- India semaglutide patents expire March 2026
-- China has 17+ generic semaglutide candidates in Phase 3 trials
-- Oral Wegovy launched January 2026 at $149-$299/month
-- Medicare negotiated oral Wegovy price: $245/month
-- Sandoz, Apotex, and Teva filed for Canadian generic semaglutide immediately after patent expiry
-- Biomm + Biocon (India) preparing generic semaglutide for Brazil market